CN108685961A - 一种改善学习记忆组合物及制剂，其制备方法及应用 - Google Patents
一种改善学习记忆组合物及制剂，其制备方法及应用 Download PDFInfo
- Publication number
- CN108685961A CN108685961A CN201810931658.2A CN201810931658A CN108685961A CN 108685961 A CN108685961 A CN 108685961A CN 201810931658 A CN201810931658 A CN 201810931658A CN 108685961 A CN108685961 A CN 108685961A
- Authority
- CN
- China
- Prior art keywords
- memory
- capsule
- content
- learning
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 44
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 230000006872 improvement Effects 0.000 title claims description 4
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims abstract description 22
- 235000019198 oils Nutrition 0.000 claims abstract description 19
- 241000219226 Acer truncatum Species 0.000 claims abstract description 17
- 241000168517 Haematococcus lacustris Species 0.000 claims abstract description 17
- 235000015112 vegetable and seed oil Nutrition 0.000 claims abstract description 17
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 claims abstract description 16
- 235000010591 Appio Nutrition 0.000 claims abstract description 16
- 239000004148 curcumin Substances 0.000 claims abstract description 11
- 235000012754 curcumin Nutrition 0.000 claims abstract description 11
- 229940109262 curcumin Drugs 0.000 claims abstract description 11
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000007901 soft capsule Substances 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 7
- 229940079593 drug Drugs 0.000 claims abstract description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 43
- 239000002775 capsule Substances 0.000 claims description 26
- 239000003292 glue Substances 0.000 claims description 25
- 235000011187 glycerol Nutrition 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 108010010803 Gelatin Proteins 0.000 claims description 16
- 229920000159 gelatin Polymers 0.000 claims description 16
- 239000008273 gelatin Substances 0.000 claims description 16
- 235000019322 gelatine Nutrition 0.000 claims description 16
- 235000011852 gelatine desserts Nutrition 0.000 claims description 16
- 240000007087 Apium graveolens Species 0.000 claims description 15
- 238000001035 drying Methods 0.000 claims description 9
- 238000007599 discharging Methods 0.000 claims description 8
- 239000012467 final product Substances 0.000 claims description 8
- 239000011159 matrix material Substances 0.000 claims description 8
- 239000003605 opacifier Substances 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 238000004321 preservation Methods 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- 239000003086 colorant Substances 0.000 claims description 7
- 235000013402 health food Nutrition 0.000 claims description 3
- 230000007131 anti Alzheimer effect Effects 0.000 claims description 2
- 235000013305 food Nutrition 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- KKAJSJJFBSOMGS-UHFFFAOYSA-N 3,6-diamino-10-methylacridinium chloride Chemical compound [Cl-].C1=C(N)C=C2[N+](C)=C(C=C(N)C=C3)C3=CC2=C1 KKAJSJJFBSOMGS-UHFFFAOYSA-N 0.000 claims 1
- 244000273928 Zingiber officinale Species 0.000 claims 1
- 235000006886 Zingiber officinale Nutrition 0.000 claims 1
- 235000008397 ginger Nutrition 0.000 claims 1
- 238000002844 melting Methods 0.000 claims 1
- 230000008018 melting Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 16
- 208000024827 Alzheimer disease Diseases 0.000 abstract description 4
- 206010039966 Senile dementia Diseases 0.000 abstract description 4
- 230000036541 health Effects 0.000 abstract description 3
- 239000004615 ingredient Substances 0.000 abstract description 2
- 244000101724 Apium graveolens Dulce Group Species 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000006870 function Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000001343 mnemonic effect Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- 239000003921 oil Substances 0.000 description 16
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical group O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 10
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 9
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 9
- 229960002646 scopolamine Drugs 0.000 description 9
- 210000005013 brain tissue Anatomy 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 102000019197 Superoxide Dismutase Human genes 0.000 description 7
- 108010012715 Superoxide dismutase Proteins 0.000 description 7
- 239000000084 colloidal system Substances 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 239000008279 sol Substances 0.000 description 7
- 238000010792 warming Methods 0.000 description 7
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 108090000371 Esterases Proteins 0.000 description 5
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 5
- 229960004373 acetylcholine Drugs 0.000 description 5
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 239000004408 titanium dioxide Substances 0.000 description 5
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 4
- 201000001880 Sexual dysfunction Diseases 0.000 description 4
- -1 anesin Chemical compound 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 231100000872 sexual dysfunction Toxicity 0.000 description 4
- 241000208140 Acer Species 0.000 description 3
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 3
- 206010012289 Dementia Diseases 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000013793 astaxanthin Nutrition 0.000 description 3
- 239000001168 astaxanthin Substances 0.000 description 3
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 3
- 229940022405 astaxanthin Drugs 0.000 description 3
- 235000013871 bee wax Nutrition 0.000 description 3
- 239000012166 beeswax Substances 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 230000002000 scavenging effect Effects 0.000 description 3
- GWHCXVQVJPWHRF-KTKRTIGZSA-N (15Z)-tetracosenoic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCCCC(O)=O GWHCXVQVJPWHRF-KTKRTIGZSA-N 0.000 description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 208000026139 Memory disease Diseases 0.000 description 2
- XJXROGWVRIJYMO-SJDLZYGOSA-N Nervonic acid Natural products O=C(O)[C@@H](/C=C/CCCCCCCC)CCCCCCCCCCCC XJXROGWVRIJYMO-SJDLZYGOSA-N 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical group NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000001387 apium graveolens Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- GHBFNMLVSPCDGN-UHFFFAOYSA-N caprylic acid monoglyceride Natural products CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- GWHCXVQVJPWHRF-UHFFFAOYSA-N cis-tetracosenoic acid Natural products CCCCCCCCC=CCCCCCCCCCCCCCC(O)=O GWHCXVQVJPWHRF-UHFFFAOYSA-N 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 230000007087 memory ability Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 229950008882 polysorbate Drugs 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- 229940083466 soybean lecithin Drugs 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 240000001592 Amaranthus caudatus Species 0.000 description 1
- 235000009328 Amaranthus caudatus Nutrition 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000018152 Cerebral disease Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 102000003914 Cholinesterases Human genes 0.000 description 1
- 108090000322 Cholinesterases Proteins 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 241000168525 Haematococcus Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 235000000177 Indigofera tinctoria Nutrition 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000004178 amaranth Substances 0.000 description 1
- 235000012735 amaranth Nutrition 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- JYTVKRNTTALBBZ-UHFFFAOYSA-N bis demethoxycurcumin Natural products C1=CC(O)=CC=C1C=CC(=O)CC(=O)C=CC1=CC=CC(O)=C1 JYTVKRNTTALBBZ-UHFFFAOYSA-N 0.000 description 1
- PREBVFJICNPEKM-YDWXAUTNSA-N bisdemethoxycurcumin Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)CC(=O)\C=C\C1=CC=C(O)C=C1 PREBVFJICNPEKM-YDWXAUTNSA-N 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000006229 carbon black Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940048961 cholinesterase Drugs 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- YXAKCQIIROBKOP-UHFFFAOYSA-N di-p-hydroxycinnamoylmethane Natural products C=1C=C(O)C=CC=1C=CC(=O)C=C(O)C=CC1=CC=C(O)C=C1 YXAKCQIIROBKOP-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 238000000895 extractive distillation Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 239000008236 heating water Substances 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 229940097275 indigo Drugs 0.000 description 1
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 230000007074 memory dysfunction Effects 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000019476 oil-water mixture Nutrition 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 150000002926 oxygen Chemical class 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- ULSIYEODSMZIPX-UHFFFAOYSA-N phenylethanolamine Chemical compound NCC(O)C1=CC=CC=C1 ULSIYEODSMZIPX-UHFFFAOYSA-N 0.000 description 1
- 229960004526 piracetam Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 150000003248 quinolines Chemical group 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/05—Chlorophycota or chlorophyta (green algae), e.g. Chlorella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/20—Aceraceae (Maple family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Nutrition Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明公开了一种显著改善学习型记忆组合物，其组成包含姜黄素、雨生红球藻脂溶性抽提物、元宝枫籽油和芹菜籽油，本发明配方组成物质理化性质相似、成分及功能不同、作用机理各异，通过多靶点协同作用达到显著提高学习记忆的技术效果，且对人体无毒副作用，可以广泛用于制备改善学习记忆和预防治疗老年痴呆的药物和保健品，本发明还提供了一种包含上述组合物的软胶囊及其制备方法，其制备方法简单，适于工业化生产。
Description
技术领域
本发明涉及一种改善学习记忆组合物及制剂，其制备方法和应用，属于医药保健品领域。
背景技术
学习和记忆能力是人类赖以生存所必不可缺少的重要脑功能，学习和记忆力下降会严重影响其生活和社会适应能力，大大降低其生活质量和社会存在感。记忆能力的下降甚至退化与人体健康状况、大脑生理老化、大脑创伤以及病理性变化等有着密切的关系。除此之外，经济、社会飞速发展所带来的压力也会导致不同年龄阶层的人出现记忆紊乱，从而影响正常生活。有资料表明，约5％～15％的老年人有不同程度的痴呆症状，严重者给社会和家庭带来很大精神和经济负担。且不少年轻人群由于生活工作压力巨大，出现学习记忆力减退的现象也越来越多。
目前众多研究者已从不同角度提出了记忆力衰退的发病机制学说，如胆碱功能低下假说、基因突变假说、淀粉样蛋白假说、炎症或免疫假说、氧化应激及兴奋性毒性假说、凋亡假说等。然而，医学研究表明，对于老年痴呆症至今还没有特效药物和治疗方法。因此研究开发具有改善学习记忆功能的医药保健品，具有重要的经济和社会应用价值。
发明内容
本发明的目的在于提供一种具有改善学习记忆组合物及制剂，其制备方法和应用。
本发明的目的之一是通过以下技术方案实现的。
一种改善学习记忆能力组合物，按重量份计包含以下组分：姜黄素0.3-2份、雨生红球藻脂溶性抽提物1-3份、元宝枫籽油10-30份、芹菜籽油1-3份。
优选地，上述改善学习记忆能力组合物，按重量份计包含以下组分：姜黄素0.5-1份、雨生红球藻脂溶性抽提物1.2-2份、元宝枫籽油15-20份、芹菜籽油1.5-2份。
上述雨生红球藻脂溶性抽提物制备方法为：新鲜雨生红球藻置高压均质机中破壁，收集藻渣，用CO2超临界萃取4h，温度75℃，压力40MPa，CO2流速25L/h，收集脂溶性抽提物，所得脂溶性抽提物中虾青素含量≥5％。
上述元宝枫籽油制备方法为:元宝枫种仁加热至85～90℃蒸炒40min,选用95型螺旋榨油机物理压榨,得元宝枫籽油,所述元宝枫籽油中神经酸的含量≥5％。
上述芹菜籽油可以直接购买市售样品，或者自行制备，其制备方法为：芹菜籽用烘箱干燥处理后粉碎，过60目筛备用。称取一定量过筛后样品置于圆底烧瓶，加入9倍量蒸馏水，浸泡23h,加热沸腾产生过热水蒸气在常压下蒸馏8h，同时在溶剂瓶中加入适量乙醚，50℃水浴加热，同步循环萃取蒸馏出芹菜籽油，收集油水混合液，加入适量无水硫酸钠干燥除去水分，过滤，滤液旋转蒸发除去溶剂，得淡黄绿色芹菜籽油。
本发明组合物中的姜黄素具有抗炎症、抗氧化、免疫调节、抑制aβ蛋白聚集等作用；元宝枫籽油含有功能性脂肪酸神经酸，是世界科学家公认的、能修复疏通受损大脑神经通路神经纤维并促使神经细胞再生的双效神奇物质，它的缺乏，将会引起脑中风后遗症、老年痴呆、脑瘫、脑萎缩、记忆力减退、失眠健忘等脑疾病；雨生红球藻脂溶性抽提物中主要成分虾青素是世界上最强的天然抗氧化剂之一，抗氧化活性超过现有的抗氧化剂。而芹菜籽油能改善局灶性脑缺血大脑损伤程度，同时对神经细胞也有一定的保护作用。四者联合应用从不同的方面发挥作用，能够有效改善学习记忆力、老年痴呆症等症状。且组合物中四种成分均可用于保健食品，可长期使用，安全无毒。
综上所述，本发明组合物可应用于制备具有改善学习记忆，抗阿尔兹海默病等药品、保健食品、特殊功能性食品等。
本发明还提供了一种改善学习记忆能力软胶囊，其由胶囊内容物、胶皮组成。其中，胶囊内容物由权利要求1-2所述改善学习记忆组合物、0种或几种药学可接受辅料基质组成；胶皮由明胶、甘油、水、药学可接受的遮光剂、药学可接受的着色剂中的1种或几种组成。
所述药学上接受辅料基质为稀释剂、防腐剂、助悬剂等，稀释剂可为聚乙二醇、丙二醇、聚山梨酯、甘油、花生油、玉米油、豆油等，防腐剂选自苯甲酸、山梨酸、三氯叔丁醇、苯甲醇、对羟基苯甲酸甲酯等；助悬剂选自蜂蜡、氢化植物油、氢化蓖麻油、阿拉伯胶、大豆卵磷脂、可可油、辛酸丙二醇酯、辛酸甘油酯、羧甲基纤维素、羟丙基纤维素、羟乙基甲基纤维素等。
所述遮光剂可为二氧化钛、氧化铁或炭黑，所述着色剂可为氧化铁红、苋菜红、胭脂红、柠檬黄或靛蓝等。
其制备方法包含以下步骤：
(1)胶囊内容物制备：按内容物处方量称取各组分，置于洁净容器搅拌混合30min，置胶体磨中研磨2～3次，抽真空脱泡(真空度-0.06～-0.08Mpa)出料，静置2小时，观察混合物均以透明、无气泡，即得胶囊内容物。
(2)溶胶：按胶皮处方量称取明胶、甘油、水，将甘油和水置溶胶罐中加热至40～50℃，投入明胶并升温至70～80℃，搅拌30min，使之完全熔融，加入遮光剂或着色剂，保温1h，抽真空脱泡，观察胶液透明无气泡后过100目筛，60±5℃保温，得胶液。
(3)压丸、定型、洗丸、干燥、捡丸、包装即得。
附图说明
图1、图2为组合物对东莨菪碱诱导记忆获得性障碍小鼠避暗试验行为的影响
图3为组合物对东莨菪碱诱导记忆获得性障碍小鼠脑组织乙酰胆碱酯酶活性的影响
图4为组合物对东莨菪碱诱导记忆获得性障碍小鼠脑组织超氧化物歧化酶活性影响
图5为组合物对东莨菪碱诱导记忆获得性障碍小鼠脑组织丙二醛含量影响
具体实施方式
为了更好的理解本发明，下面通过具体实施例对本发明作进一步说明，但不以任何方式对本发明加以限制，基于本发明教导所作的任何变化或替换，均属本发明保护范围。
下面实施例中所用样品，姜黄素、芹菜籽油直接购买市售样品，雨生红球藻脂溶性抽提物和元宝枫籽油为自制样品，其制备方法见实施例1和2
实施例1雨生红球藻脂溶性抽提物制备
取新鲜雨生红球藻2kg，置高压均质机中破壁，收集藻渣，后用CO2超临界萃取4h，温度75℃，压力40MPa，CO2流速25L/h，收集脂溶性抽提物，制得雨生红球藻脂溶性抽提物550g，其中虾青素含量6％。
实施例2元宝枫籽油制备
取元宝枫种仁4kg，加热至85～90℃蒸炒40min,用95型螺旋榨油机物理压榨,得元宝枫籽油1.4kg,其中神经酸含量为6％。
实施例3组合物软胶囊制备
胶囊内容物处方：组合物198g(其中：姜黄素3g、雨生红球藻脂溶性抽提物30g、元宝枫籽油150g、芹菜籽油15g)；辅料基质40g(包含：聚乙二醇400、大豆卵磷脂)。
软胶囊制备：(制成1000粒)
(1)胶囊内容物制备：按内容物处方量称取各组分，置于洁净容器搅拌混合30min，置胶体磨中研磨2～3次，抽真空脱泡(真空度-0.06～-0.08Mpa)出料，静置2小时，观察混合物均以透明、无气泡，即得胶囊内容物。
(2)溶胶:称取明胶200g、甘油100g、水200g，将甘油和水置溶胶罐中加热至40～50℃，投入明胶并升温至70～80℃，搅拌30min，使之完全熔融，加入遮光剂二氧化钛，保温1h，抽真空脱泡，观察胶液透明无气泡后过100目筛，60±5℃保温，得胶液。
(3)压丸、定型、洗丸、干燥、捡丸、包装即得。
实施例4组合物软胶囊制备
胶囊内容物处方：组合物350g(其中：姜黄素20g、雨生红球藻脂溶性抽提物10g、元宝枫籽油300g、芹菜籽油20g)。
软胶囊制备：(制成1000粒)
(1)胶囊内容物制备：按内容物处方量称取各组分，置于洁净容器搅拌混合30min，置胶体磨中研磨2～3次，抽真空脱泡(真空度-0.06～-0.08Mpa)出料，静置2小时，观察混合物均以透明、无气泡，即得胶囊内容物。
(2)溶胶：称取明胶200g、甘油120g、水200g，将甘油和水置溶胶罐中加热至40～50℃，投入明胶并升温至70～80℃，搅拌30min，使之完全熔融，加入遮光剂二氧化钛，保温1h，抽真空脱泡，观察胶液透明无气泡后过100目筛，60±5℃保温，得胶液。
(3)压丸、定型、洗丸、干燥、捡丸、包装即得。
实施例5组合物软胶囊制备
胶囊内容物处方：组合物252g(姜黄素10g、雨生红球藻脂溶性抽提物12g、元宝枫籽油200g份、芹菜籽油30g)；辅料基质45g(包含：玉米油、苯甲酸)。
软胶囊制备：(制成1000粒)
(1)胶囊内容物制备：按内容物处方量称取各组分，置于洁净容器搅拌混合30min，置胶体磨中研磨2～3次，抽真空脱泡(真空度-0.06～-0.08Mpa)出料，静置2小时，观察混合物均以透明、无气泡，即得胶囊内容物。
(2)溶胶：称取明胶200g、甘油80g、水190g，将甘油和水置溶胶罐中加热至40～50℃，投入明胶并升温至70～80℃，搅拌30min，使之完全熔融，加入着色剂胭脂红，保温1h，抽真空脱泡，观察胶液透明无气泡后过100目筛，60±5℃保温，得胶液。
(3)压丸、定型、洗丸、干燥、捡丸、包装即得。
实施例6组合物软胶囊制备
胶囊内容物处方：组合物135g(姜黄素5g、雨生红球藻脂溶性抽提物20g、元宝枫籽油100g、芹菜籽油10g)；辅料基质22g(包含：聚山梨酯、丙二醇、大豆卵磷脂、山梨酸)。
软胶囊制备：(制成1000粒)
(1)胶囊内容物制备：按内容物处方量称取各组分，置于洁净容器搅拌混合30min，置胶体磨中研磨2～3次，抽真空脱泡(真空度-0.06～-0.08Mpa)出料，静置2小时，观察混合物均以透明、无气泡，即得胶囊内容物。
(2)溶胶：称取明胶200g、甘油120、水220g，将甘油和水置溶胶罐中加热至40～50℃，投入明胶并升温至70～80℃，搅拌30min，使之完全熔融，加入二氧化钛和氧化铁红，保温1h，抽真空脱泡，观察胶液透明无气泡后过100目筛，60±5℃保温，得胶液。
(3)压丸、定型、洗丸、干燥、捡丸、包装即得。
实施例7组合物软胶囊制备
胶囊内容物处方：组合物252g(姜黄素10g、雨生红球藻脂溶性抽提物12g、元宝枫籽油200g、芹菜籽油30g)；辅料基质35g(包含：甘油、蜂蜡、对羟基苯甲酸乙酯)。
软胶囊制备：(制成1000粒)
(1)胶囊内容物制备：按内容物处方量称取各组分，置于洁净容器搅拌混合30min，置胶体磨中研磨2～3次，抽真空脱泡(真空度-0.06～-0.08Mpa)出料，静置2小时，观察混合物均以透明、无气泡，即得胶囊内容物。
(2)溶胶：称取明胶200g、甘油100g、水200g，将甘油和水置溶胶罐中加热至40～50℃，投入明胶并升温至70～80℃，搅拌30min，使之完全熔融，加入着色剂芹菜红，保温1h，抽真空脱泡，观察胶液透明无气泡后过100目筛，60±5℃保温，得胶液。
(3)压丸、定型、洗丸、干燥、捡丸、包装即得。
实施例8组合物软胶囊制备
胶囊内容物处方：组合物185g(姜黄素5g、雨生红球藻脂溶性抽提物15g、元宝枫籽150g、芹菜籽油15g)、辅料基质22g(包括：花生油、蜂蜡)。
软胶囊制备：(制成1000粒)
(1)胶囊内容物制备：按内容物处方量称取各组分,置于洁净容器搅拌混合30min，置胶体磨中研磨2～3次，抽真空脱泡(真空度-0.06～-0.08Mpa)出料，静置2小时，观察混合物均以透明、无气泡，即得胶囊内容物。
(2)溶胶：称取明胶200g、甘油110g、水200g，将甘油和水置溶胶罐中加热至40～50℃，投入明胶并升温至70～80℃，搅拌30min，使之完全熔融，加入遮光剂二氧化钛，保温1h，抽真空脱泡，观察胶液透明无气泡后过100目筛，60±5℃保温，得胶液。
(3)压丸、定型、洗丸、干燥、捡丸、包装即得。
下面通过动物实验例1来说明本发明组合物的药理效果
试验例1
实验动物：SPF级雄性KM小鼠，体重20-25g，饲养环境：室温(23±2)℃，相对湿度50％-60％，12/12h明暗交替，自由饮食、摄水。小鼠于实验前7d置于实验室适应环境。
实验动物分组及处理:
将48只KM小鼠随机分成4组，模型+组合物组、模型+脑复康组、模型组和空白对照组。模型组和空白对照组均以等量的生理盐水灌胃，阳性对照组给西药脑复康0.3g/kg，组合物组给予实施例4制备软胶囊内容物0.35g/kg,各组均按10ml/kg/b.w.灌胃给药(空白组和模型组灌胃等量生理盐水)，每天一次，连续28d。在最后一次给药1h后，除空白组腹腔注射生理盐水外，其他组均腹腔注射东莨菪碱(3mg/kg/b.w.)制备小鼠学习记忆障碍模型，并于注射20min后进行避暗试验。
避暗试验：
该试验分为习得测试(Acquisition trial)和记忆保持测试(Retention trial)两部分。小鼠灌胃第26天起，连续2d在同一时间将小鼠放入避暗仪中适应5min。第28天腹腔注射东莨菪碱20min后开始习得测试，将小鼠背对拱门放入明箱后，给暗室不锈钢栅栏通以0.3mA电流持续5min，由于小鼠具有趋暗的习性会由明室向暗室探索，小鼠一进入暗室即受电击，其正确反应是回到明室，记录小鼠第1次进入暗室的时间即为避暗潜伏期，步入潜伏期大于5min者弃去不用,5min内小鼠进入暗室的次数即为穿梭次数,作为习得成绩；24h后对小鼠进行记忆保持测试，记录小鼠5min内的潜伏期及进入暗室的次数(即穿梭次数)，作为记忆成绩，5min内未进入暗室的小鼠其潜伏期按300s计，穿梭次数计0次。
小鼠血浆、脑组织内生化指标检测：
行为学试验结束后，乙醚麻醉小鼠，摘眼球取血，全血离心后取血清；脱颈椎处死小鼠，迅速于冰上断头取脑，加9倍体积(m/V)的冰生理盐水进行匀浆。4℃离心(3000r/min，10min)，取上清液，即为10％组织匀浆。分别按照试剂盒说明书测定脑组织匀浆中乙酰胆碱酯酶活性、过氧化物歧化酶活性和丙二醛活性，采用考马斯亮兰法测定组织蛋白含量。
实验结果：
1.小鼠避暗试验行为表现
试验结果见图1、图2，由图1、图2可知,在习得测试时，各组间潜伏期与穿梭次数均无显著性差异(P>0.05)。在记忆保持测试时，与空白组相比，模型组潜伏期显著缩短，穿梭次数显著增加，表明腹腔注射东莨菪碱使小鼠产生学习记忆障碍。与模型组相比，组合物组和阳性对照组潜伏期显著延长，穿梭次数减少，表明组合物能显著改善痴呆小鼠学习记忆的能力。
2.小鼠脑组织乙酰胆碱酯酶活性
实验结果见图3，从图可以看出与空白组对比，模型组乙酰胆碱酯酶活性显著升高，组合物组和阳性对照组和模型组比较乙酰胆碱酯酶活性均显著降低，说明本发明组合物能够抑制东莨菪碱诱发的胆碱酯酶活性的升高。
3.小鼠脑组织超氧化物歧化酶活性和丙二醛含量
超氧化物歧化酶活性(SOD)是机体内唯一直接特异性地能够使细胞损伤减少的物质，众多研究认为自由基与老年性痴呆症有重要关系，丙二醛(MDA)活性的高低不仅能分析出体内氧自由基水平的高低程度，还能分析出细胞损伤的程度。所以，在测定生化指标时经常同时检测MDA和SOD的活性，机体清除氧自由基能力的高低可以通过SOD活性测定来反映，机体受自由基侵袭的严重度可以通过MDA活性测定来反映。实验结果见图4和图5，结果显示，和对照组比较，模型组小鼠超氧化物歧化酶活性降低，丙二醛含量升高，表明东莨菪碱损伤小鼠清除自由基能力。组合物组和阳性对照组与模型组比较，超氧化物歧化酶活性升高，丙二醛含量降低，表明本发明组合物能提高机体清除自由基能力。与空白组相比，组合物组和阳性对照组超氧化物歧化酶活性，丙二醛活性基本恢复正常水平，说明本发明组合物能够较好的增强东莨菪碱致衰小鼠脑组织中抗氧化酶活力，减少氧化产物含量，从而减轻组织过氧化损伤。
Claims (5)
1.一种改善学习记忆的组合物，其特征在于，所述组合物按重量份计包含以下成分：姜黄素0.3-2份、雨生红球藻脂溶性抽提物1-3份、元宝枫籽油10-30份、芹菜籽油1-3份。
2.如权利要求1所述改善学习记忆的组合物，其特征在于，按重量份计包含以下组分：姜黄素0.5-1份、雨生红球藻脂溶性抽提物1.2-2份、元宝枫籽油15-20份、芹菜籽油1.5-2份。
3.权利要求1-2所述改善学习记忆组合物，在制备具有改善学习记忆，抗阿尔兹海默病等药品、保健食品、特殊功能性食品等方面的应用。
4.一种改善学习记忆软胶囊，其特征在于其由胶囊内容物、胶皮组成，其中，胶囊内容物由权利要求1-2所述改善学习记忆组合物、0种或几种药学可接受辅料基质组成，胶皮由明胶、甘油、水、药学可接受的遮光剂、药学可接受的着色剂中的1种或几种组成。
5.如权利要求4所述改善学习记忆能力软胶囊，其特征在于其制备方法包含以下步骤：
(1)胶囊内容物制备：按内容物处方量称取各组分，置于洁净容器搅拌混合30min，置胶体磨中研磨2～3次，抽真空脱泡，出料，静置2小时，观察混合物均一透明、无气泡，即得胶囊内容物；
(2)溶胶：按处方量称取胶皮配方组成物质，置溶胶罐中加热至70～80℃，搅拌30min使之完全熔融，加入遮光剂或着色剂，保温1h，抽真空脱泡，观察胶液透明无气泡后过100目筛，60±5℃保温，得胶液；
(3)压丸、定型、洗丸、干燥、捡丸、包装即得。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810931658.2A CN108685961B (zh) | 2018-08-16 | 2018-08-16 | 一种改善学习记忆组合物及制剂，其制备方法及应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810931658.2A CN108685961B (zh) | 2018-08-16 | 2018-08-16 | 一种改善学习记忆组合物及制剂，其制备方法及应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108685961A true CN108685961A (zh) | 2018-10-23 |
| CN108685961B CN108685961B (zh) | 2020-12-29 |
Family
ID=63841298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810931658.2A Active CN108685961B (zh) | 2018-08-16 | 2018-08-16 | 一种改善学习记忆组合物及制剂，其制备方法及应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108685961B (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115837038A (zh) * | 2022-11-18 | 2023-03-24 | 厦门大学 | 一种雨生红球藻提取物的制备及其应用 |
| CN117045760A (zh) * | 2023-07-20 | 2023-11-14 | 深圳市金枫生物医药科技有限公司 | 一种神经修复组合物及其制备方法和应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107375368A (zh) * | 2017-06-02 | 2017-11-24 | 杭州鑫伟低碳技术研发有限公司 | 一种预防心血管疾病修复神经系统产品及其制备方法 |
| CN107736526A (zh) * | 2017-10-11 | 2018-02-27 | 杭州鑫伟低碳技术研发有限公司 | 一种具有改善记忆力的保健饮料及其制备方法 |
-
2018
- 2018-08-16 CN CN201810931658.2A patent/CN108685961B/zh active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107375368A (zh) * | 2017-06-02 | 2017-11-24 | 杭州鑫伟低碳技术研发有限公司 | 一种预防心血管疾病修复神经系统产品及其制备方法 |
| CN107736526A (zh) * | 2017-10-11 | 2018-02-27 | 杭州鑫伟低碳技术研发有限公司 | 一种具有改善记忆力的保健饮料及其制备方法 |
Non-Patent Citations (2)
| Title |
|---|
| 徐成: "芹菜籽油对脑衰老和脑缺血的防治作用及机制探讨", 《沈阳药科大学硕士学位论文》 * |
| 梅全喜: "《现代中药药理与临床应用手册》", 31 October 2016, 中国中医药出版社 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115837038A (zh) * | 2022-11-18 | 2023-03-24 | 厦门大学 | 一种雨生红球藻提取物的制备及其应用 |
| CN117045760A (zh) * | 2023-07-20 | 2023-11-14 | 深圳市金枫生物医药科技有限公司 | 一种神经修复组合物及其制备方法和应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108685961B (zh) | 2020-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103735733B (zh) | 一种含叶黄素酯的复方制剂及其制备方法 | |
| CN105358170B (zh) | 辛弗林或其盐在制备用于治疗或预防特异反应性皮炎的组合物中的应用 | |
| CN106690287A (zh) | 一种具有缓解视疲劳功能的组合物及其制备方法 | |
| CN103566049A (zh) | 用于提高眼睛中视黄斑色素密度并预防或治疗年龄相关性视黄斑衰退症的组合物 | |
| CN105125736A (zh) | 一种保肝明目功效的组合物及其制备方法 | |
| CN101708048B (zh) | 一种保健食品及其制备方法 | |
| CN105998195A (zh) | 一种具有抗敏感保湿作用的汉麻提取物及其应用 | |
| CN108157575A (zh) | 一种缓解视疲劳的压片糖果及其制备方法与应用 | |
| CN100574772C (zh) | 一种含叶黄素的软胶囊及其制备方法 | |
| CN109123612A (zh) | 一种具有增强免疫力功效的组合物、保健食品及其制备方法 | |
| CN106539083A (zh) | 一种用于预防和治疗糖尿病视网膜病变、缓解视力疲劳的组合物 | |
| CN105030877A (zh) | 一种缓解视疲劳的保健食品及其制备方法 | |
| CN108685961A (zh) | 一种改善学习记忆组合物及制剂，其制备方法及应用 | |
| CN107106624A (zh) | 预防、改善或治疗退行性神经系统疾病的含桑葚和茯苓皮的混合提取物的组合物 | |
| KR100712249B1 (ko) | 생약재 추출물을 함유하는 지성피부 개선용 화장료 조성물및 그 제조방법 | |
| CN101474383B (zh) | 大蒜总皂苷的制备方法及其产品和应用 | |
| CN109662318A (zh) | 一种具有抗氧化功能的黑果腺肋花楸制剂及其制备方法 | |
| CN107259566A (zh) | 一种稳定高效护眼、提高视力的组合物及制备方法和应用 | |
| CN106690201A (zh) | 一种具有增强免疫力功能的组合物及其制备方法 | |
| CN108066384A (zh) | 一种具有增强免疫力功能的中药制剂及其制备方法 | |
| CN109619587A (zh) | 一种具有缓解视疲劳功效的黑果腺肋花楸制剂及其制备方法 | |
| CN102150860A (zh) | 一种用于缓解视疲劳和辅助改善记忆的组合物 | |
| CN108888682A (zh) | 一种明目护眼组合物 | |
| CN108079169A (zh) | 用于预防和治疗动脉粥样硬化及其并发症的中药组合物、中药制剂及应用 | |
| CN105816549B (zh) | 一种防治动脉粥样硬化斑块的药物及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20220707 Address after: 310000 room 1702, unit 4, building 4, jinjinjiayuan, Shangcheng District, Hangzhou, Zhejiang Province Patentee after: Liao Aihua Address before: Room 211-1, 2nd floor, building a, Yunnan Overseas Students Pioneer Park Phase I, University Science Park, 1520 Haiyuan Middle Road, high tech Zone, Kunming, Yunnan 650106 Patentee before: YUNNAN DECAITANG BIOMEDICAL TECHNOLOGY CO.,LTD. |
|
| TR01 | Transfer of patent right |